PD-L1

PD-L1

PD-L1, or “programmed-death ligand 1” (also known as CD274 or B7-H1) is a membrane bound glycoprotein in the B7 family of cell surface ligands involved in regulation of the immune system. PD-L1 is expressed on a variety of inflammatory-activated cells, some carcinomas, and in melanoma (ovary, colon, lung, breast, and renal cell carcinomas). PD-L1 expression on tumor cells is correlated with poor prognosis in patients with cancers such as NSCLC, esophageal cancer, and pancreatic carcinoma. Levels of PD-L1 are increased in the plasma of cancer patients as well as in cerebrospinal fluid of gliomas. sPD-L1 is a biomarker of poor survival in patients with B cell lymphoma, renal cell carcinoma, metastatic melanoma or lung cancer, and is associated with advanced tumor stage. PD-L1 contributes to immune evasion by binding to PD-1 and CD80 to suppress the activation and proliferation of T cells and induce apoptosis of activated T cells. Blocking the PD-1/PD-L1 pathway to prevent this immune evasion and restore anti-tumor immunity has emerged as a promising anti-cancer strategy.

Safety Data Sheets

The following Safety Data Sheets are associated with this Assay.

This website uses cookies. By continuing to use this website you are acknowledging and agree with our cookie policy.

AgreeLearn more